The UK corticosteroid guidance for Duchenne muscular dystrophy has now been translated into Spanish, Italian, German, and French, helping make this important information more accessible to clinicians across Europe. It is essential to highlight that these documents were originally developed by clinicians based in the UK and within the context of the UK healthcare system and clinical practice. For this reason, any use or interpretation of the guidance outside the UK should be approached with careful consideration of local medical frameworks, policies, and standards of care. The translations were supported by a grant from Santhera Pharmaceuticals. Please find translated guidance documents for corticosteroid use in DMD on this page.